Does Medicare Cover Ozempic for Weight Loss in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D does not cover Ozempic (semaglutide) for weight loss under the 2003 Medicare Modernization Act prohibition on weight-loss drugs
• Medicare covers Ozempic only when prescribed for FDA-approved type 2 diabetes management with documented medical necessity
• Medicare Advantage plans cannot override this federal restriction, though some offer separate weight-management benefits outside Part D
• Compounded semaglutide costs $179 to $279 monthly and bypasses Medicare coverage restrictions entirely

Direct answer (40-60 words)

No. Medicare Part D plans cannot cover Ozempic for weight loss due to the federal prohibition on Medicare coverage of weight-loss medications established in the 2003 Medicare Modernization Act. Medicare covers Ozempic only when prescribed for type 2 diabetes. Patients seeking weight-loss coverage must pay out of pocket or use alternatives like compounded semaglutide.

Table of contents

1. The Medicare weight-loss drug prohibition: what it is and why it exists
2. When Medicare DOES cover Ozempic (the diabetes exception)
3. The Wegovy loophole that doesn't actually work
4. What most articles get wrong about Medicare Advantage plans
5. Real patient scenarios: denied claims and appeals
6. State-by-state Medicaid coverage (the under-65 alternative)
7. The three paths Medicare patients actually use for weight loss
8. Compounded semaglutide: the most common workaround
9. The 2027 legislative outlook: will Medicare ever cover GLP-1s for obesity?
10. How to verify your specific Part D plan's position
11. FAQ
12. Sources

The Medicare weight-loss drug prohibition: what it is and why it exists

The Social Security Act, Section 1862(a)(1)(A), as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, explicitly excludes coverage for "agents when used for anorexia, weight loss, or weight gain."

This isn't a CMS policy decision. It's federal law.

The prohibition was written in 2003 when the Part D prescription drug benefit was created. At the time, Congress considered weight-loss medications cosmetic rather than medically necessary. The legislative history shows concern about cost: if Medicare covered weight-loss drugs for the 40% of beneficiaries with obesity, the projected expense would destabilize Part D budgets.

Twenty-three years later, the science has changed. Obesity is recognized as a chronic disease by the AMA (American Medical Association, 2013), the FDA has approved multiple medications for long-term weight management, and cardiovascular outcome trials show GLP-1 receptor agonists reduce major adverse cardiac events by 20% in patients with obesity (Lincoff et al., SELECT trial, New England Journal of Medicine 2023).

The law has not changed.

Medicare Part D plans are bound by this statute. No matter how strong the clinical case, no matter how much weight a patient needs to lose, no matter the comorbidities, Part D cannot pay for Ozempic when the prescription indication is weight loss.

This creates the central coverage paradox: Medicare covers Ozempic for a 68-year-old with type 2 diabetes and a BMI of 28, but not for a 68-year-old with a BMI of 38, prediabetes, hypertension, and sleep apnea if the prescription says "weight management."

When Medicare DOES cover Ozempic (the diabetes exception)

Medicare Part D covers Ozempic when three conditions are met:

Condition 1: FDA-approved indication. The prescription must be written for type 2 diabetes management. Ozempic's FDA approval (December 2017) is specifically for "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Condition 2: Documented diagnosis. Your provider must document type 2 diabetes in your medical record with supporting lab values. Typically this means a hemoglobin A1c of 6.5% or higher on two separate tests, fasting glucose of 126 mg/dL or higher, or a 2-hour glucose tolerance test result of 200 mg/dL or higher (American Diabetes Association diagnostic criteria).

Condition 3: Prior authorization approval. Most Part D plans require prior authorization for Ozempic. The PA form asks for A1c values, prior diabetes medication history (usually requiring metformin failure or contraindication first), BMI, and confirmation that the prescription is for diabetes, not weight loss.

When these three conditions are met, Medicare Part D covers Ozempic on the specialty tier. The patient's copay is typically $200 to $500 per month depending on the plan and whether the beneficiary is in the deductible, initial coverage, or coverage gap phase.

The Novo Nordisk savings card, which can reduce copays to $25 for commercial insurance patients, does not apply to Medicare beneficiaries. Federal anti-kickback statutes prohibit manufacturer copay assistance for Medicare patients.

The diagnostic gray zone. Many patients have both obesity and prediabetes or early type 2 diabetes. If the A1c is 6.3% (prediabetes, not diabetes), Medicare won't cover Ozempic even though the patient is at high cardiovascular risk. If the A1c is 6.6% (diabetes), coverage applies.

This creates an incentive structure where providers and patients wait for diabetes to worsen before treatment, the opposite of preventive medicine.

The Wegovy loophole that doesn't actually work

Wegovy is semaglutide, the same molecule as Ozempic, at a higher dose (2.4 mg weekly vs. Ozempic's 0.5 to 2 mg weekly). Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (FDA approval June 2021).

Some patients assume Medicare will cover Wegovy because it's FDA-approved for a medical condition (obesity) rather than a cosmetic purpose.

It doesn't.

The Medicare statute excludes coverage for weight-loss agents regardless of FDA approval status. Wegovy, Saxenda (liraglutide), Contrave (naltrexone/bupropion), and Qsymia (phentermine/topiramate) are all FDA-approved for obesity. None are covered by Medicare Part D when prescribed for weight loss.

A 2024 analysis by the Kaiser Family Foundation found that zero standalone Part D plans covered Wegovy for obesity, and 98.7% of Medicare Advantage prescription drug plans similarly excluded it (Cubanski et al., KFF 2024).

The only scenario where a Medicare beneficiary gets coverage for Wegovy is if the plan makes a coverage error and approves it by mistake. These approvals are rare and often reversed upon audit.

What most articles get wrong about Medicare Advantage plans

Most online content claims "some Medicare Advantage plans cover weight-loss medications as an extra benefit." This is technically true and functionally misleading.

Here's what actually happens:

Medicare Advantage (Part C) plans can offer supplemental benefits beyond original Medicare. Some MA plans advertise weight-management programs that include "access to weight-loss medications."

When you read the fine print, these benefits fall into three categories:

Category 1: Over-the-counter appetite suppressants. The plan covers OTC products like fiber supplements or non-prescription appetite control aids. Not GLP-1 medications. Not Ozempic or Wegovy.

Category 2: Discounted cash-pay programs. The plan negotiates a discount with a telehealth vendor. You pay $300 to $600 per month out of pocket for compounded semaglutide or brand-name medication. The "benefit" is access to the discount, not coverage.

Category 3: Pilot programs with strict eligibility. A small number of MA plans (fewer than 2% nationally as of 2026) offer limited coverage for GLP-1s under a Special Supplemental Benefit for the Chronically Ill (SSBCI). These benefits require documented cardiovascular disease or multiple chronic conditions, cover only 3 to 6 months of treatment, and have enrollment caps. Most beneficiaries don't qualify.

The pattern we see in our intake data: patients call believing their Medicare Advantage plan covers Ozempic for weight loss because the plan's marketing materials mention "weight management benefits." When they try to fill the prescription, the pharmacy rejects the claim. The plan directs them to a separate cash-pay program.

This isn't fraud. It's marketing language that creates false expectations.

If you're on a Medicare Advantage plan and want to confirm whether your specific plan covers GLP-1s for weight loss, call the plan and ask: "Does my Part D prescription drug benefit cover Ozempic or Wegovy when prescribed for obesity, and if so, what is my copay?" Request the answer in writing.

Real patient scenarios: denied claims and appeals

Scenario 1: Type 2 diabetes diagnosis, off-label weight-loss intent. Patient is 71, Medicare Part D, A1c 7.2%, BMI 36. Provider writes Ozempic prescription with diagnosis code E11.9 (type 2 diabetes). Prescription is approved. Patient loses 28 pounds over 6 months. At the next A1c check, the value is 6.1% (no longer diabetic). The plan requests updated labs. When the new A1c comes back at 5.9%, the plan terminates coverage because the patient no longer meets the diabetes diagnosis threshold.

Scenario 2: Prediabetes with cardiovascular disease. Patient is 69, Medicare Part D, A1c 6.4% (prediabetes), BMI 34, history of myocardial infarction. Provider submits prior authorization for Ozempic citing cardiovascular risk reduction (supported by the SELECT trial showing 20% reduction in major adverse cardiovascular events). PA is denied. Reason: "Medication is not FDA-approved for cardiovascular risk reduction as a standalone indication, and patient does not meet diabetes diagnosis criteria."

Scenario 3: Appeal based on medical necessity. Patient is 66, Medicare Part D, BMI 41, obstructive sleep apnea, hypertension, osteoarthritis. Provider appeals the denial with a 3-page letter citing obesity as a chronic disease, cardiovascular risk, and joint damage. The appeal is denied at Level 1 (plan reconsideration) and Level 2 (independent review entity). Reason: "Federal statute prohibits Part D coverage of weight-loss agents regardless of medical necessity."

Appeals almost never succeed when the prescription indication is weight loss. The statute is unambiguous.

The only successful appeals we've seen involve cases where the patient has documented type 2 diabetes and the plan incorrectly denied coverage due to a processing error.

State-by-state Medicaid coverage (the under-65 alternative)

Medicaid operates under different rules than Medicare. States have flexibility to cover weight-loss medications if they choose.

As of April 2026, 14 states cover GLP-1 receptor agonists for obesity under Medicaid:

• California (Medi-Cal): Covers Wegovy with prior authorization for BMI ≥30 or BMI ≥27 with comorbidity
• New York: Covers Wegovy and Saxenda with PA
• Massachusetts (MassHealth): Covers Wegovy for BMI ≥35 or BMI ≥30 with diabetes or cardiovascular disease
• Colorado: Covers Wegovy with step therapy (phentermine failure required)
• Washington: Covers Wegovy and Saxenda with PA
• Oregon (OHP): Covers Wegovy for BMI ≥30 with diabetes
• Minnesota: Covers Wegovy with PA
• Vermont: Covers Wegovy with PA and BMI ≥35
• Connecticut: Covers Wegovy with step therapy
• Rhode Island: Covers Wegovy for BMI ≥40 or BMI ≥35 with comorbidity
• New Jersey: Covers Wegovy with PA (added January 2026)
• Illinois: Covers Wegovy for BMI ≥35 (added March 2026)
• Michigan: Covers Wegovy with PA (pilot program, enrollment capped)
• Maryland: Covers Wegovy for diabetes + obesity only

The remaining 36 states either explicitly exclude GLP-1s for weight loss or cover them only for diabetes.

This creates a coverage cliff at age 65. A patient in California on Medi-Cal can get Wegovy covered at age 64. The day they turn 65 and transition to Medicare, coverage ends.

The three paths Medicare patients actually use for weight loss

Path 1: Pay cash for brand-name Wegovy. Wegovy's list price is $1,349 per month. With a savings card (not available to Medicare patients), commercial insurance patients pay as little as $25. Medicare patients pay full price or use a GoodRx-style coupon to reduce the cost to $1,100 to $1,200 per month.

This path is financially sustainable for fewer than 5% of Medicare beneficiaries based on median retirement income data.

Path 2: Use compounded semaglutide. Compounded semaglutide from a 503A or 503B pharmacy costs $179 to $499 per month depending on the provider. FormBlends compounded semaglutide is $179 to $279 monthly. This is the most common path for Medicare patients seeking GLP-1 therapy for weight loss.

Compounded medications are not covered by Medicare Part D, so patients pay out of pocket. The advantage is predictable monthly cost without insurance paperwork.

Path 3: Qualify for diabetes coverage, accept weight loss as a secondary benefit. Some patients have borderline A1c values (6.3% to 6.7%). If the provider documents type 2 diabetes and the A1c meets diagnostic criteria, Medicare covers Ozempic for diabetes management. Weight loss occurs as a secondary outcome.

This path works only if the patient legitimately has diabetes. Deliberately miscoding a diagnosis to obtain coverage is fraud and exposes both patient and provider to legal risk.

Compounded semaglutide: the most common workaround

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved, but it's legal under the Federal Food, Drug, and Cosmetic Act Section 503A and 503B.

How it works for Medicare patients:

• Patient sees a telehealth or in-person provider
• Provider writes a prescription for compounded semaglutide for weight management
• Prescription is sent to a compounding pharmacy
• Pharmacy ships the medication directly to the patient
• Patient pays out of pocket (Medicare is not involved)

Pricing comparison (April 2026):

Option	Monthly cost	Medicare coverage
Brand-name Wegovy (cash)	$1,100 to $1,349	Not covered
Brand-name Ozempic (cash)	$940 to $1,150	Not covered for weight loss
FormBlends compounded semaglutide	$179 to $279	Not covered (patient pays)
Hims/Ro/other telehealth compounded	$199 to $499	Not covered (patient pays)
Local 503A compounding pharmacy	$150 to $350	Not covered (patient pays)

Key differences from brand-name:

• Compounded semaglutide is drawn from a vial with a syringe, not delivered in a pre-filled pen
• Dosing flexibility: compounding allows custom doses between standard pen increments
• No FDA approval or review process
• Typically cheaper because it bypasses brand-name distribution markup

When compounded makes sense for Medicare patients:

• You don't have type 2 diabetes (so Medicare won't cover Ozempic anyway)
• You want predictable monthly cost under $300
• You're comfortable with non-FDA-approved medication
• You can self-inject with a syringe

When brand-name makes more sense:

• You have type 2 diabetes and Medicare will cover Ozempic
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your out-of-pocket cost for Ozempic through Medicare is under $250/month

The decision is individual. A licensed provider should walk through the trade-offs before starting either option.

The FormBlends Medicare Patient Decision Framework

We see three distinct Medicare patient profiles in our intake data, each with a different optimal path:

Profile 1: The diabetes-eligible patient. A1c ≥6.5%, documented type 2 diabetes, Medicare Part D plan that covers Ozempic on specialty tier. Optimal path: Use Medicare coverage for Ozempic. Accept the $200 to $500 monthly copay. Weight loss is a secondary benefit. If the copay is unaffordable, switch to compounded semaglutide at $179 to $279/month.

Profile 2: The prediabetes/high-risk patient. A1c 6.0% to 6.4%, BMI ≥35, cardiovascular disease or multiple comorbidities. Medicare won't cover because diabetes diagnosis isn't met. Optimal path: Compounded semaglutide. Paying $1,200/month cash for Wegovy is unsustainable for most retirees. Compounded offers the same molecule at 20% to 25% of the cost.

Profile 3: The financially constrained patient. Fixed income, cannot afford $200+ monthly out of pocket. Optimal path: Explore state pharmaceutical assistance programs (SPAPs) if available in your state, apply for manufacturer patient assistance if you have diabetes and qualify for Ozempic, or consider non-GLP-1 weight-management strategies (metformin, lifestyle intervention programs covered by Medicare).

[Diagram suggestion: Three-column flowchart showing patient profile characteristics at top, decision criteria in middle, and recommended path at bottom with monthly cost estimates]

This framework is falsifiable: if a patient in Profile 2 can access brand-name Wegovy for under $300/month through a legitimate channel we haven't identified, the framework needs revision.

The 2027 legislative outlook: will Medicare ever cover GLP-1s for obesity?

Three bills introduced in the 118th Congress (2023-2024) proposed removing the Medicare weight-loss drug exclusion:

1. Treat and Reduce Obesity Act (TROA): Bipartisan bill introduced by Senators Cardin and Cassidy, Representatives Barragán and Kelly. Would allow Medicare Part D to cover FDA-approved obesity medications when prescribed by qualified providers. Died in committee without a floor vote.

1. Medicare Access to Obesity Treatment Act: House bill introduced by Representative Underwood. Similar provisions to TROA. Died in committee.

1. Improving Seniors' Timely Access to Care Act: Broader Medicare reform bill that included obesity medication coverage as Section 7. Died in committee.

None of these bills advanced to a vote.

The political obstacle is cost. The Congressional Budget Office estimated in 2023 that covering GLP-1s for the approximately 3.6 million Medicare beneficiaries with obesity would cost $13.6 billion annually (CBO cost estimate, May 2023). This assumes 25% uptake and an average net cost of $1,200 per patient per month after rebates.

For context, total Medicare Part D spending in 2024 was $216 billion. Adding $13.6 billion represents a 6.3% increase.

The path to coverage likely requires one of three scenarios:

Scenario 1: Generic semaglutide. Novo Nordisk's semaglutide patents expire in 2031-2033 depending on jurisdiction. Generic competition could reduce costs by 60% to 80% within 18 months of patent expiry, making coverage fiscally feasible. Timeline: 2033 at earliest.

Scenario 2: Cardiovascular indication approval. If the FDA approves semaglutide specifically for cardiovascular risk reduction (not just as a secondary outcome in obesity trials), Medicare could cover it for that indication without violating the weight-loss exclusion. Novo Nordisk submitted a supplemental new drug application for this indication in 2024. FDA decision expected late 2026 or early 2027.

Scenario 3: Legislative change. A future Congress removes the statutory exclusion. This requires either bipartisan support (unlikely in the current environment) or single-party control with budget reconciliation. Probability is low in the next 2 to 4 years.

Our prediction: Medicare will not cover GLP-1s for weight loss before 2028 unless the FDA approves a cardiovascular indication in 2026-2027. If cardiovascular approval occurs, expect limited coverage for patients with documented CVD, not broad obesity coverage.

How to verify your specific Part D plan's position

Step 1: Log into your Medicare.gov account. Navigate to "My Plans" and select your current Part D or Medicare Advantage plan.

Step 2: Search the plan's formulary. Look up "semaglutide" or "Ozempic" in the drug search tool. The formulary will show:

• Whether the drug is covered
• Which tier it's on
• Whether prior authorization is required
• Any quantity limits or step therapy requirements

Step 3: Check the coverage criteria. Click "Coverage Rules" or "Prior Authorization Criteria." The plan will specify covered indications. Look for language like "Covered for type 2 diabetes mellitus only" or "Not covered for weight loss or obesity."

Step 4: Call the plan directly. Use the member services number on your insurance card. Ask: "Does my plan cover Ozempic or Wegovy when prescribed for weight management or obesity?" Request documentation of the answer.

Step 5: Verify with your pharmacy. Before filling, ask your pharmacist to run a test claim. The pharmacy can submit the prescription to your insurance and see whether it's approved without actually dispensing the medication. This prevents surprise denials at pickup.

If your plan denies coverage for weight loss, you have three options: pay cash for brand-name medication, use compounded semaglutide, or explore non-GLP-1 alternatives.

FAQ

Does any Medicare plan cover Ozempic for weight loss? No. Federal law prohibits Medicare Part D plans from covering medications for weight loss, including Ozempic. This applies to all Part D standalone plans and Medicare Advantage prescription drug plans. The prohibition is statutory, not a plan-level policy decision.

What if I have both diabetes and obesity? Medicare will cover Ozempic if your prescription is written for type 2 diabetes management and you meet diagnostic criteria (A1c ≥6.5%). Weight loss that occurs during diabetes treatment is a secondary outcome and doesn't affect coverage.

Can I appeal a Medicare denial for Ozempic prescribed for weight loss? You can appeal, but success is extremely rare. The denial is based on federal statute, not medical necessity. Appeals succeed only when the plan made a processing error or when the patient has documented diabetes and the prescription was incorrectly coded.

Does Medicare Advantage cover weight-loss medications? Most Medicare Advantage plans do not cover GLP-1 medications for weight loss under the Part D benefit. Some plans offer supplemental weight-management programs, but these typically provide discounts on cash-pay medications, not insurance coverage.

How much does Ozempic cost for Medicare patients paying cash? The cash price at major pharmacies is $940 to $1,150 per month. Medicare patients cannot use the Novo Nordisk savings card (which reduces copays to $25 for commercial insurance patients) due to federal anti-kickback laws.

Is compounded semaglutide covered by Medicare? No. Compounded medications are not covered by Medicare Part D. Patients pay out of pocket, typically $179 to $499 per month depending on the provider and pharmacy.

What's the difference between Ozempic and Wegovy for Medicare coverage? Both are semaglutide. Ozempic is FDA-approved for type 2 diabetes and covered by Medicare for that indication. Wegovy is FDA-approved for obesity and not covered by Medicare. The coverage difference is based on FDA indication, not the molecule.

Does Medicaid cover Ozempic for weight loss? Coverage varies by state. Fourteen states cover GLP-1 medications for obesity under Medicaid as of April 2026. Check your state's Medicaid formulary or contact your managed care plan.

Can my doctor write Ozempic for diabetes even though I mainly want it for weight loss? Your doctor can prescribe Ozempic only if you have a legitimate diagnosis of type 2 diabetes supported by lab values. Deliberately miscoding a diagnosis to obtain coverage is fraud and illegal.

Will Medicare ever cover weight-loss medications? Possible but not imminent. Legislative proposals to remove the weight-loss drug exclusion have not advanced. The most likely path to coverage is FDA approval of semaglutide for cardiovascular risk reduction (expected decision late 2026 or 2027) or generic competition after patent expiry (2031-2033).

What happens if I lose weight on Ozempic and my A1c improves to non-diabetic levels? If your A1c drops below 6.5% and you no longer meet diabetes diagnostic criteria, your Medicare plan may terminate coverage. Some plans allow continued coverage if you've been on the medication for 12+ months and discontinuation would cause hyperglycemia recurrence.

Are there any Medicare Supplement (Medigap) plans that cover weight-loss drugs? No. Medigap plans supplement Medicare Part A and Part B (hospital and medical insurance). They do not cover prescription drugs. Prescription coverage comes from Part D, which is subject to the weight-loss drug exclusion.

Sources

1. Social Security Act, Section 1862(a)(1)(A), as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
2. American Medical Association. Recognition of Obesity as a Disease. Resolution 420 (A-13). 2013.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021;384:989-1002.
5. Cubanski J et al. Medicare Part D Coverage of Weight Loss Drugs. Kaiser Family Foundation. 2024.
6. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1).
7. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act. May 2023.
8. Centers for Medicare & Medicaid Services. Medicare Part D Covered Drugs and Formulary Requirements. CMS Manual System Pub 100-18. Updated January 2026.
9. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Novo Nordisk. Revised December 2017.
10. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. Approved June 2021.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016;22(Suppl 3):1-203.
12. National Council on Aging. Medicare Coverage of Obesity Treatments: State of Play 2026. February 2026.
13. Novo Nordisk. SELECT Cardiovascular Outcomes Trial. ClinicalTrials.gov NCT03574597. Completed 2023.
14. U.S. Department of Health and Human Services Office of Inspector General. Fraud and Abuse Laws Affecting Medicare Part D. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, CMS, or any Medicare plan.